ResMed outlines FY 2027 $5.75B-$5.85B revenue outlook while targeting $1.85B+ shareholder returns (NYSE:RMD)

seekingalpha.com · 2026-10-30

ResMed Q1 FY2027: revenue rose 7%, EPS jumped 14%, guidance held, and Astral sales ended.